NCT01573702View on ClinicalTrials.gov

Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR)

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

December 11, 2012

Primary Completion Date

March 15, 2019

Study Completion Date

March 15, 2019

Conditions
Non Small Cell Lung Cancer
Interventions
PROCEDURE

Stereotactic Radiosurgery

21 Gy daily for 5 days

DRUG

Erlotinib

150mg once daily

Trial Locations (8)

15232

University of Pittsburgh Medical Center, Pittsburgh

19111

Fox Chase Cancer Center, Philadelphia

27599

Lineberger Comprehensive Cancer Center, Chapel Hill

27834

East Carolina University, Greenville

44195

STO Taussig Cancer Center; Cleveland Clinic, Cleveland

80045

University of Colorado Cancer Center, Aurora

94115

University of California at San Francisco, San Francisco

98104

Swedish Cancer Institute, Seattle

All Listed Sponsors
collaborator

Astellas Pharma Global Development, Inc.

INDUSTRY

lead

UNC Lineberger Comprehensive Cancer Center

OTHER

NCT01573702 - Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR) | Biotech Hunter | Biotech Hunter